Sotatercept: clinical use

Prescribing considerations

• Initiation and monitoring should be undertaken by a physician experienced in diagnosing and treating PAH.
• Use only as an adjunct to other PAH therapies in adults within the licensed functional classes.
• Assess baseline haemoglobin, platelet count, bleeding risk, pregnancy potential and suitability for self-administration.
• Use additional caution with erythrocytosis, thromboembolic risk, prostacyclin infusion, antithrombotic treatment or current serious bleeding.
• Evidence is limited for PAH associated with HIV, portal hypertension, schistosomiasis or pulmonary veno-occlusive disease.

Contraindications and cautions

• Hypersensitivity to sotatercept or an excipient.
• Platelet count consistently below 50 × 10^9/L before treatment initiation.

Monitoring

• Haemoglobin and platelet count before treatment, frequently during early treatment and periodically once stable.
• Evidence of serious bleeding, thrombosis, hyperviscosity, hypertension or worsening hypoxaemia.
• Preparation and administration technique, particularly after a kit change or development of erythrocytosis.
• Record the product name and batch number for biological traceability.

Clinical pharmacology

Sotatercept is a recombinant ActRIIA-Fc ligand trap that inhibits activin signalling and rebalances vascular growth pathways. It is catabolised through general protein-degradation processes and has a terminal half-life of approximately 21 days.

Formulation and product differences

• Supplied as powder with sterile water for reconstitution rather than a ready-to-use solution.
• One-vial and two-vial kits are available; kit selection is weight-dependent.
• The reconstituted solution is single-use and should be clear to opalescent, without clumps or residual powder.

Injection

Route: Parenteral

Strengths: 45 mg, 60 mg